| Ytd | -55.13% | |
| 1y | -52.49% |
| Open | 1.01 | Prev Close | 1.03 | Low | 1.01 | High | 1.05 | Mkt Cap | 10.35M |
| Vol | 19.66K | Avg Vol | 59.58K | EPS | -1.30 | P/E | N/A | Forward P/E | -0.80 |
| Beta | 0.24 | Short Ratio | 0.51 | Inst. Own | 46.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 1.23 | 200-d Avg | 1.61 | 1yr Est | 4.75 |
INAB News
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus
Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant
After losing some value lately, a hammer chart pattern has been formed for IN8bio (INAB), indicating
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-d
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmac
Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, dri
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.26) per share which beat the analyst consensus
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Repor
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”),
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical
IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety pr
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta
NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutica
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac
IN8bio (NASDAQ: INAB - Get Free Report) and Cadrenal Therapeutics (NASDAQ: CVKD - Get Free Report) a
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio's
IN8bio, Inc. (the "Company") presented consolidated data, a summary of which is located belo
Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrat
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-d
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compo
Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progressio
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmac
U.S. stock futures were flat on Monday after closing higher on Friday. Futures of major benchmark in